Ann Hohenhaus, DVM, DACVIM (Oncology, SAIM), delved into essential components of a diagnostic investigation of dogs with MCRs ...

Nearly 25 years ago, Ann and Jim Pride endured the unimaginable when their son Jeff — a happy boy who liked the color blue ...

During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

oncology, and transplant medicine from 24 countries. It is held in association with prestigious international hospitals, including the Children's Hospital of Philadelphia, Ann & Robert H. Lurie ...

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...

When Ann Duginske Cibulka first decided to join up with Ryan Cos., one of her bosses told her that the health care market was ...

Mizuho Securities analyst Ann Hynes maintained a Buy rating on Ardent Health Partners, Inc. (ARDT – Research Report) yesterday. The ...

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Lineage Therap (LCTX – Research Report). The ...

SCIENTISTS and clinicians in Leeds exploring new radiotherapy techniques have been given a major cash boost from Cancer ...

Ianalumab (previously known as VAY736) is a novel BAFF-targeting antibody that was recently evaluated in patients with pSS.

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...